Indexing
CÁC SỐ TỪ 2011-2023
Tạp chí Y Dược Học
Abstract
Background: Modified high-dose dual therapy (mHDDT), consisting of a proton pump inhibitor and amoxicillin, utilizes fewer drugs while maintaining efficacy for H. pylori eradication, particularly in regions with low amoxicillin resistance. Objectives: This study aimed to evaluate the eradication efficacy of mHDDT (rabeprazole-amoxicillin) compared to bismuth-containing quadruple therapy (RBMT) in patients with H. pylori-infected gastroduodenal diseases and to assess adverse effects, treatment adherence, clinical symptom improvement, and endoscopic outcomes. Materials and Methods: A randomized controlled trial was conducted at the University of Medicine and Pharmacy Hospital, Hue University, from April 2022 to August 2023. A total of 103 H. pylori-infected patients were randomly assigned to either the mHDDT group or the RBMT group. Results: Based on intention-to-treat analysis, the eradication rates were 80.0% for the mHDDT group and 81.1% for the RBMT group (p = 0.810). Per-protocol analysis showed rates of 81.6% and 86.0%, respectively (p = 0.555). Notably, the incidence of adverse events was significantly lower in the mHDDT group (30.6%) compared to the RBMT group (84.0%) (p < 0.001). Treatment adherence was higher in the mHDDT group (91.8% vs. 78.0%), although this difference did not reach statistical significance (p = 0.055). Conclusion: The mHDDT regimen is an simple treatment option, offering comparable efficacy to RBMT for H. pylori eradication and improvements in clinical symptoms and gastroduodenal mucosal healing with significantly fewer side effects.
| Published | 2026-06-28 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 3 (2026) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2026.3.931 | |
| Keywords |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Hue Journal of Medicine and Pharmacy
a học Tiêu hóa Việt Nam 2018, IX(53): 3284-3293.
Nguyễn Thị Hiền. Nghiên cứu hiệu quả tiệt trừ Helicobacter pylori của phác đồ 2 thuốc liều cao Rabeprazole và Amoxicillin 14 ngày ở bệnh nhân bị viêm dạ dày mạn [Luận Án Chuyên Khoa Cấp II], Huế: Đại học Y Dược Huế; 2017
Öztürk K. et al. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol 2020, 31(3): 234-238.
Zhu Y. J., Zhang Y., Wang T. Y., Zhao J. T., et al. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol 2020, 13: 1756284820937115
Nam T Phan, Long H Truong. Effectiveness of 14-day high-dose dual therapy for Helicobacter pylori infection in Vietnam. Journal of Infection in Developing Countries 2025; 19(3):404-408
Chen Li-Wei et al. The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial. Journal of Clinical Medicine 2021, 10: 4352.
Bộ Y tế, Dược thư quốc gia Việt Nam. Nhà xuất bản Y Học; 2018; 188-191, 1228-1230.
Phan T. N. et al. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. Int J Antimicrob Agents 2015, 45(3): 244-248.
Zhou Ben-Gang et al. High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Therapeutic Advances in Gastroenterology 2023, 16.
Hồ Tấn Phát và cộng sự. Đánh giá hiệu quả của phác đồ 2 thuốc liều cao ở bệnh nhân nhiễm Helicobacter pylori đã thất bại điều trị trước đó tại Bệnh viện Chợ Rẫy. Y Học TP Hồ Chí Minh 2021, 25(3): 133-140.
Yang-Jie Zhu et al. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therapeutic Advances in Gastroenterology 2020, 13.